Tudor Investment Corp’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-19,524
| Closed | -$2.77M | – | 4066 |
|
|
2025
Q4 | $2.77M | Sell |
19,524
-7,336
| -27% | -$1.06M | 0.01% | 1571 |
|
|
2025
Q3 | $3.77M | Buy |
26,860
+23,893
| +805% | +$3.24M | 0.01% | 1387 |
|
|
2025
Q2 | $373K | Buy |
+2,967
| New | +$340K | ﹤0.01% | 2761 |
|
|
2024
Q1 | – | Sell |
-3,574
| Closed | -$471K | – | 2593 |
|
|
2023
Q4 | $471K | Sell |
3,574
-45,245
| -93% | -$5.21M | ﹤0.01% | 1826 |
|
|
2023
Q3 | $5.49M | Buy |
+48,819
| New | +$5.14M | 0.06% | 464 |
|
|
2023
Q2 | – | Sell |
-5,016
| Closed | -$508K | – | 2770 |
|
|
2023
Q1 | $508K | Sell |
5,016
-43,036
| -90% | -$4.48M | 0.01% | 1613 |
|
|
2022
Q4 | $5.74M | Buy |
+48,052
| New | +$5.63M | 0.11% | 209 |
|
|
2022
Q3 | – | Sell |
-42,694
| Closed | -$4.16M | – | 2570 |
|
|
2022
Q2 | $4.16M | Buy |
42,694
+39,675
| +1,314% | +$3.66M | 0.11% | 221 |
|
|
2022
Q1 | $283K | Sell |
3,019
-41,521
| -93% | -$3.52M | 0.01% | 1584 |
|
|
2021
Q4 | $3.79M | Buy |
44,540
+15,028
| +51% | +$1.38M | 0.06% | 362 |
|
|
2021
Q3 | $2.83M | Buy |
29,512
+5,452
| +23% | +$515K | 0.05% | 511 |
|
|
2021
Q2 | $2.34M | Buy |
+24,060
| New | +$2.31M | 0.04% | 499 |
|
|
2021
Q1 | – | Sell |
-26,854
| Closed | -$2.57M | – | 1755 |
|
|
2020
Q4 | $2.57M | Sell |
26,854
-11,898
| -31% | -$1.15M | 0.07% | 327 |
|
|
2020
Q3 | $3.73M | Buy |
+38,752
| New | +$4.48M | 0.16% | 122 |
|
|
2020
Q1 | – | Sell |
-28,537
| Closed | -$3.07M | – | 1230 |
|
|
2019
Q4 | $3.07M | Buy |
28,537
+25,377
| +803% | +$2.66M | 0.14% | 171 |
|
|
2019
Q3 | $285K | Buy |
+3,160
| New | +$295K | 0.01% | 870 |
|
|
2019
Q2 | – | Sell |
-10,419
| Closed | -$918K | – | 1257 |
|
|
2019
Q1 | $918K | Sell |
10,419
-10,739
| -51% | -$898K | 0.04% | 495 |
|
|
2018
Q4 | $1.51M | Sell |
21,158
-2,000
| -9% | -$192K | 0.03% | 271 |
|
|
2018
Q3 | $2.85M | Buy |
+23,158
| New | +$2.63M | 0.07% | 187 |
|
|
2018
Q2 | – | Sell |
-8,941
| Closed | -$741K | – | 1165 |
|
|
2018
Q1 | $741K | Sell |
8,941
-19,927
| -69% | -$1.68M | 0.02% | 431 |
|
|
2017
Q4 | $2.24M | Buy |
+28,868
| New | +$1.97M | 0.06% | 144 |
|
|
2017
Q3 | – | Sell |
-5,428
| Closed | -$250K | – | 1200 |
|
|
2017
Q2 | $250K | Buy |
+5,428
| New | +$263K | 0.01% | 818 |
|
|
2015
Q2 | – | Sell |
-6,635
| Closed | -$263K | – | 1612 |
|
|
2015
Q1 | $263K | Buy |
+6,635
| New | +$237K | 0.01% | 1125 |
|
|
2013
Q4 | – | Sell |
-30,900
| Closed | -$350K | – | 1327 |
|
|
2013
Q3 | $350K | Buy |
+30,900
| New | +$425K | 0.01% | 513 |
|
Other funds holding NBIX
VPM
VCM
Tudor Investment Corp's NBIX Position: Q1 2026 in Review
Tudor Investment Corp sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 19,524 shares — an estimated $2.77M sold.
Tudor Investment Corp first reported a position in NBIX in Q3 2013 and held it in 24 quarters. The position peaked at $5.74M in Q4 2022. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Tudor Investment Corp reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
- Tudor Investment Corp sold 19,524 Neurocrine Biosciences shares in Q1 2026, an estimated $2.77M.
- Tudor Investment Corp first reported a position in Neurocrine Biosciences in Q3 2013 and held it in 24 quarters.
- Tudor Investment Corp's Neurocrine Biosciences position peaked at $5.74M in Q4 2022.
- 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.